COMPANY

CASI Pharmaceuticals

Keywords: antibody monoclonal antibody immunology autoimmune diseases Ovarian Cancer Multiple Myeloma Recurrent Glioblastoma Multiforme Antibody Mediated Rejection Chronic Immune Thrombocytopenia Advanced Adult Hepatocellular Carcinoma Advanced Fibrolamellar Carcinoma Triple Negative Breast Cancer Fallopian Cancer Peritoneal Cancer Non-Small Cell Lung Cancer Endometrial Cancer Relapsed or Refractory Hematological Malignancies Metastatic Renal Cell Carcinoma Pancreatic Cancer Carcinoid Tumor Breast Cancer Hematological Malignancies Myelodysplasia Agnogenic Myeloid Metaplasia Relapsed Multiple Myeloma Non-Small-Cell Lung Carcinoma Prostate Cancer CID-103 ENMD-2076 MKC-1 Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab) 2-methoxyestradiol Panzem Nanocrystal Colloidal Dispersion Panzem Nanocrystal Colloidal Dispersion (NCD) Panzem® NCD

Profile checked Oct 10, 2026

$20.0MRaised (2 yrs)23Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $5M in debt securities (Form D filed Apr 28, 2026); +3 other Form D filings in the last 12 months. SEC Form D 0001962738-26-000004 (Apr 28, 2026)
Evidence (4 events)
- Apr 28, 2026 · SEC Form D 0001962738-26-000004
  Name of Issuer: CASI Pharmaceuticals, Inc.; CIK: 1962738; Address: Beijing, China; Submission type: D; Filing date: 2026-04-28; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-17; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b
- Feb 26, 2026 · SEC Form D 0001962738-26-000003
  Name of Issuer: CASI Pharmaceuticals, Inc.; CIK: 1962738; Address: Beijing, China; Submission type: D; Filing date: 2026-02-26; Industry Group: Pharmaceuticals; Date of First Sale: 2026-02-19; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b
- Jan 28, 2026 · SEC Form D 0001962738-26-000002
  Name of Issuer: CASI Pharmaceuticals, Inc.; CIK: 1962738; Address: Beijing, China; Submission type: D; Filing date: 2026-01-28; Industry Group: Pharmaceuticals; Date of First Sale: 2026-01-09; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b
- Jan 28, 2026 · SEC Form D 0001962738-26-000001
  Name of Issuer: CASI Pharmaceuticals, Inc.; CIK: 1962738; Address: Beijing, China; Submission type: D; Filing date: 2026-01-28; Industry Group: Pharmaceuticals; Date of First Sale: 2025-12-27; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jun 9, 2026 Trial start Phase 1/Phase 2: A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR). source ↗
Dec 11, 2025 Raise Private placement — Convertible note: $20M (up to, as announced), announced Dec 11, 2025. Source: SEC filing. source ↗
Jan 3, 2025 Trial start Phase 1/Phase 2: A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia source ↗
Mar 22, 2021 Trial start Phase 1: CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma source ↗
2015-10 Trial start Phase 2: A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma source ↗
2012-07 Trial start 2: Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC source ↗
2010-04 Trial start Phase 2: Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer source ↗
2009-04 Trial start Phase 1: Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies source ↗
2008-12 Trial start Phase 1: Study of ENMD-2076 in Patients With Multiple Myeloma source ↗
2008-04 Trial start Phase 1: A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer source ↗
2008-03 Trial start 1: Phase 1 Study of MKC-1 in Patients With Advanced Cancer source ↗
2008-01 Trial start 2: A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer source ↗
2007-11 Trial start 2: Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer source ↗
2007-04 Trial start 2: Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM) source ↗
2007-02 Trial start 2: Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma source ↗
2006-11 Trial start 1: A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies source ↗
2006-11 Trial start Phase 2: Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer source ↗
2006-10 Trial start Phase 1/Phase 2: Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer source ↗
2006-10 Trial start Phase 2: Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer source ↗
2006-05 Trial start Phase 2: A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors source ↗
2006-01 Trial start Phase 2: A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1 source ↗
2006-01 Trial start Phase 2: Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma source ↗
2001-03 Trial start 2: A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma source ↗

Upcoming milestones

2030-05 (ESTIMATED) · Phase 1/Phase 2 · A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR). · NCT07641426

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $20.0M. Last 2 years.

Dec 11, 2025 Private placement — Convertible note: $20M (up to, as announced), announced Dec 11, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 23

Record	Title	Phase	Status	Start	Primary completion
NCT07641426	A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).	Phase 1/Phase 2	Recruiting	Jun 9, 2026	2030-05 (estimated)
NCT07017725	A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia	Phase 1/Phase 2	Recruiting	Jan 3, 2025	Jun 1, 2026 (estimated)
NCT02234986	A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma	Phase 2	Completed	2015-10	Jun 30, 2018 (actual)
NCT04758767	CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma	Phase 1	Completed	Mar 22, 2021	Jan 19, 2023 (actual)
NCT00658671	A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer	Phase 1	Completed	2008-04	2010-12 (actual)
NCT00806065	Study of ENMD-2076 in Patients With Multiple Myeloma	Phase 1	Completed	2008-12	2011-11 (actual)
NCT01639248	Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC	2	Completed	2012-07	2017-06 (actual)
NCT01104675	Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer	Phase 2	Completed	2010-04	2011-08 (actual)
NCT00408226	Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer	Phase 1/Phase 2	Completed	2006-10	2009-06 (actual)
NCT00607607	A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer	2	Completed	2008-01	2011-06 (actual)
NCT00904787	Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies	Phase 1	Completed	2009-04	2010-12 (actual)
NCT00444314	Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma	2	Completed	2007-02	2008-12 (actual)
NCT00568646	Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer	2	Completed	2007-11	2009-04 (actual)
NCT00328497	A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors	Phase 2	Completed	2006-05	2008-12 (actual)
NCT00656461	Phase 1 Study of MKC-1 in Patients With Advanced Cancer	1	Completed	2008-03	2009-07 (actual)
NCT00306631	A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1	Phase 2	Completed	2006-01	2008-04 (actual)
NCT00506402	A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies	1	Completed	2006-11	2009-01 (actual)
NCT00592579	A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma	2	Completed	2001-03	2008-09 (actual)
NCT00049790	Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer	Phase 2	Completed	Not listed	Not listed
NCT00306618	Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma	Phase 2	Completed	2006-01	2007-11 (actual)
NCT00400348	Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer	Phase 2	Completed	2006-10	2008-08 (actual)
NCT00394810	Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer	Phase 2	Completed	2006-11	2008-11 (actual)
NCT00481455	Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)	2	Completed	2007-04	2007-09 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2026-04-28 Raise Private raise (SEC Form D): $5.0M sold; issuer “CASI Pharmaceuticals, Inc.”. Verified from the SEC filing. SEC filing ↗
2026-02-26 Raise Private raise (SEC Form D): $5.0M sold; issuer “CASI Pharmaceuticals, Inc.”. Verified from the SEC filing. SEC filing ↗
2026-01-28 Raise Private raise (SEC Form D): $5.0M sold; issuer “CASI Pharmaceuticals, Inc.”. Verified from the SEC filing. SEC filing ↗
2026-01-28 Raise Private raise (SEC Form D): $5.0M sold; issuer “CASI Pharmaceuticals, Inc.”. Verified from the SEC filing. SEC filing ↗